Read our latest news, and find more about us and our portfolio companies.

Why M Ventures is Investing in Synthetic Biology Companies – Meet Andreas Jurgeit

This week we interviewed someone who is passionate about startups that are transforming innovative ideas into commercial success with real-world benefits, as well as new ideas around life science technologies. Andreas Jurgeit, Investment Director of the Life Science team at M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (for simplicity called M Ventures in the US and Canada), will be speaking in the Synthetic Biology Investor Panel (sponsored by Alexandria Real Estate Equities) at SynBioBeta SF 2017 on October 4th.

Digital Health

Die Digitalisierung macht vor keinem Bereich halt – so betrifft sie auch zunehmend das Geschäft mit der Gesundheit. Start-ups mischen traditionelle Geschäftsfelder auf – ihr Vorstoß wirft viele neue Fragen auf.